<DOC>
	<DOCNO>NCT02004717</DOCNO>
	<brief_summary>This open-label , sequential dose escalation expansion study evaluate safety , tolerability , pharmacokinetics DS-8895a Japanese subject advance solid tumor .</brief_summary>
	<brief_title>Phase 1 Study DS-8895a Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor refractory standard treatment , standard treatment available . Eastern Cooperative Oncology Group performance status ( PS ) 0 1 Have follow concomitant disease history follow disease within 6 month enrollment : Cardiac failure ( NYHA â‰¥ ClassIII ) , myocardial infarction , cerebral infarction , unstable angina , arrhythmia require treatment , coronaryartery/peripheral artery bypass surgery , cerebrovascular disease , pulmonary thromboembolism , deepvein thrombosis clinically severe thromboembolic event , clinically severe pulmonary disease ( eg , interstitial pneumonia , pulmonary fibrosis , radiation pneumonia , drug induce pneumonia ) Severe uncontrolled concomitant disease . Clinically active brain metastasis define symptomatic requiring treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Oncology</keyword>
</DOC>